Search research articles
Contact Us
Filters
Showing results (171-180 of 208) with videos related to
Page
of 21
Sort By:
JCO Precision Oncology
|
October 26, 2019
Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making
Derrick L Tao, Shawna Bailey, Tomasz M Beer, et al.
Plos Biology
|
May 5, 2005
Determination of stromal signatures in breast carcinoma
Robert B West, Dimitry S A Nuyten, Subbaya Subramanian, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
February 5, 2008
Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases
Jerzy Lasota, Christopher L Corless, Michael C Heinrich, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 14, 2021
Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma
Alyssa J Penning, Alyaa Al-Ibraheemi, Michael Michal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2015
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Edgar Ben-Josef, Katherine A Guthrie, Anthony B El-Khoueiry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor
Michael C Heinrich, Robert G Maki, Christopher L Corless, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2010
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205
Philip A Philip, Jacqueline Benedetti, Christopher L Corless, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2014
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial
Christopher L Corless, Karla V Ballman, Cristina R Antonescu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
The Journal of Molecular Diagnostics : JMD
|
July 6, 2011
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry
Carol Beadling, Michael C Heinrich, Andrea Warrick, et al.
Page
of 21
Search research articles
Search
Showing results (171-180 of 208) with videos related to
Sort By:
Page
of 21
JCO Precision Oncology
|
October 26, 2019
Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making
Derrick L Tao, Shawna Bailey, Tomasz M Beer, et al.
Plos Biology
|
May 5, 2005
Determination of stromal signatures in breast carcinoma
Robert B West, Dimitry S A Nuyten, Subbaya Subramanian, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
February 5, 2008
Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases
Jerzy Lasota, Christopher L Corless, Michael C Heinrich, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 14, 2021
Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma
Alyssa J Penning, Alyaa Al-Ibraheemi, Michael Michal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2015
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Edgar Ben-Josef, Katherine A Guthrie, Anthony B El-Khoueiry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor
Michael C Heinrich, Robert G Maki, Christopher L Corless, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2010
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205
Philip A Philip, Jacqueline Benedetti, Christopher L Corless, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2014
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial
Christopher L Corless, Karla V Ballman, Cristina R Antonescu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
The Journal of Molecular Diagnostics : JMD
|
July 6, 2011
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry
Carol Beadling, Michael C Heinrich, Andrea Warrick, et al.
Page
of 21